Collegium Pharmaceutical (NASDAQ:COLL) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Tuesday, BidAskClub reports.
A number of other equities research analysts also recently weighed in on the company. SunTrust Banks began coverage on Zoetis in a report on Tuesday, March 19th. They issued a “hold” rating and a $100.00 price target for the company. Cantor Fitzgerald set a $135.00 price target on Zimmer Biomet and gave the company a “buy” rating in a report on Friday, April 26th. HC Wainwright reiterated a “buy” rating on shares of Ballard Power Systems in a report on Friday, May 3rd. Zacks Investment Research downgraded GenMark Diagnostics from a “hold” rating to a “sell” rating in a report on Wednesday, April 24th. Finally, ValuEngine downgraded Zosano Pharma from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. Three analysts have rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $26.17.
COLL stock opened at $10.84 on Tuesday. The company has a quick ratio of 1.19, a current ratio of 1.24 and a debt-to-equity ratio of 0.22. Collegium Pharmaceutical has a 52-week low of $10.41 and a 52-week high of $21.20. The business’s 50 day simple moving average is $12.08. The stock has a market cap of $361.58 million, a P/E ratio of -9.11 and a beta of 0.55.
Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Wednesday, May 8th. The specialty pharmaceutical company reported ($0.29) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.01. Collegium Pharmaceutical had a negative return on equity of 30.87% and a negative net margin of 10.36%. The business had revenue of $74.52 million during the quarter, compared to the consensus estimate of $70.10 million. Equities research analysts anticipate that Collegium Pharmaceutical will post -0.41 EPS for the current fiscal year.
In related news, CEO Joseph Ciaffoni sold 5,851 shares of the business’s stock in a transaction that occurred on Friday, May 31st. The stock was sold at an average price of $11.52, for a total transaction of $67,403.52. Following the completion of the transaction, the chief executive officer now owns 190,755 shares in the company, valued at approximately $2,197,497.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Michael Thomas Heffernan sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $11.37, for a total value of $284,250.00. Following the transaction, the director now owns 159,090 shares of the company’s stock, valued at approximately $1,808,853.30. The disclosure for this sale can be found here. Insiders sold a total of 91,144 shares of company stock valued at $1,075,506 over the last quarter. Company insiders own 8.08% of the company’s stock.
Large investors have recently added to or reduced their stakes in the stock. MERIAN GLOBAL INVESTORS UK Ltd acquired a new position in Collegium Pharmaceutical during the 1st quarter valued at approximately $26,000. First Quadrant L P CA acquired a new position in Collegium Pharmaceutical during the 1st quarter valued at approximately $36,000. BNP Paribas Arbitrage SA boosted its position in Collegium Pharmaceutical by 67,855.6% during the 1st quarter. BNP Paribas Arbitrage SA now owns 6,116 shares of the specialty pharmaceutical company’s stock valued at $93,000 after purchasing an additional 6,107 shares during the period. Oregon Public Employees Retirement Fund acquired a new position in Collegium Pharmaceutical during the 4th quarter valued at approximately $103,000. Finally, Virginia Retirement Systems ET AL acquired a new position in Collegium Pharmaceutical during the 1st quarter valued at approximately $160,000. Institutional investors and hedge funds own 94.83% of the company’s stock.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.
Read More: Key terms to understand channel trading
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.